Revolution Medicines (RVMD) CEO Michael Sells $1.1M of Stock
Key Points
- Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer of Revolution Medicines, Inc. (RVMD), sold 5,569 shares at $199.24 per share on September 16, 2026, in a planned transaction.
- Revolution Medicines shares recently traded around $182.01, sitting below their 50-day moving average but above their 200-day moving average.
- Several Wall Street firms recently updated their outlooks on the clinical-stage oncology company, which maintains a strong buy consensus ahead of its next earnings report.
Since the trade, $RVMD is down 2.6% after 1 week, down 9.2% after 1 month and down 9.2% to date (from the $195.92 close on Sep 16, 2026).
Get Revolution Medicines text alerts
We text you when insiders, Congress, analysts or big funds move on $RVMD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures
Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer of Revolution Medicines, Inc. (NasdaqGS: RVMD), sold 5,569 shares of the company's stock on September 16, 2026. The transaction was executed at an average price of $199.24 per share, resulting in a total value of about $1.11 million. According to a Form 4 filing with the SEC, the sale was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan. The stock closed at $195.92 on the day of the trade.
RVMD
Revolution Medicines, Inc.
Inside Stephen Michael Kelsey's RVMD Trade
The planned sale by Kelsey formed part of a broader wave of insider transactions at the biotechnology firm on September 16, 2026. Under the terms of the pre-arranged trading plan, Kelsey disposed of the 5,569 shares directly. The transaction code reported for the sale was S, indicating a standard open-market disposition.
Other Institutional Activity in Revolution Medicines
Large financial institutions adjusted their positions in Revolution Medicines during prior reporting periods. Farallon Capital Management LLC trimmed its holdings by 54,421 shares, ending with 13,550,796 shares valued at about $2.47 billion. Baker Bros. Advisors, LP grew its holdings by 1,888,116 shares, ending with 11,443,357 shares worth about $2.08 billion. Jupiter Topco LLC increased its stake by 5,368,072 shares, bringing its total to 10,736,145 shares worth about $1.96 billion. Darwin Global Management, Ltd. expanded its position by 8,418,823 shares, holding 10,629,822 shares valued at about $1.94 billion. Nextech Invest, Ltd. kept its position unchanged, holding 7,601,087 shares worth about $1.38 billion.
Revolution Medicines, Inc. Stock Down 3.8%
The stock recently traded around $182.01 as of October 16, 2026, which is down about 7.1% from its close of $195.92 on the day of Kelsey's trade. The shares sit about 10.4% below their 50-day moving average of $203.12 and about 20.0% above their 200-day moving average of $151.62. The company carries a market capitalization of roughly $38.14 billion.
Recent Earnings
Revolution Medicines operates as a clinical-stage precision oncology company without current profitability, posting negative trailing twelve month earnings per share of $8.87 and a negative return on equity of 79.1%. The company's next corporate earnings update is scheduled for November 4, 2026.
Insider Buying and Selling at Revolution Medicines, Inc.
Executive and insider transactions at the company included earlier sales by other officers, such as Chief Financial Officer Jack Anders and Chief Development Officer Alan B. Sandler.
Analysts Set New Price Targets
Wall Street firms updated their views on the company following the late-summer insider transactions. On September 21, 2026, B of A Securities maintained a Buy rating and raised its price target from $225.00 to $265.00. Brookline Capital initiated coverage with a Buy rating and a $318.00 price target on September 28, 2026. Truist Securities maintained a Buy rating while adjusting its price target to $240.00 on October 7, 2026. RBC Capital maintained an Outperform rating while lifting its target from $251.00 to $259.00 on October 8, 2026, and followed up by moving the target to $260.00 on October 14, 2026. Overall, the stock holds a consensus strong buy rating with a mean price target of $257.80 across 24 analyst opinions.
About Revolution Medicines
Revolution Medicines, Inc. is a Redwood City, California-based biotechnology company focused on developing novel targeted therapies for RAS-addicted cancers through its pipeline of RAS(ON) and RAS companion inhibitors. The company employs 883 people and works to advance precision oncology options for patients.
Bottom Line
Investors are watching for the company's upcoming financial results on November 4, 2026, along with any further insider Form 4 filings. Monitoring institutional portfolio adjustments and analyst target revisions will provide additional context on market sentiment for RVMD stock.
Related Filing Alerts
Source: Kelsey Stephen Michael's Form 4 filing on $RVMD (Sep 16, 2026). Written by software, not financial advice. How we make alerts